Needham Maintains Buy on Vir Biotechnology, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has maintained a 'Buy' rating on Vir Biotechnology (NASDAQ:VIR), but lowered the price target from $22 to $15.
November 03, 2023 | 11:22 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst has maintained a 'Buy' rating on Vir Biotechnology but lowered the price target from $22 to $15.
The news is directly related to Vir Biotechnology. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100